CBS has been previously characterized as having oncogenic roles in promoting tumor growth and progression, initiating tumor formation in colon, ovarian, and breast cancer, and as a potential target for cancer therapy.50 These were consistent with the observed benefit of T2T-CHM13 in the discovery of cancer driver genes’ methylation alterations in colon cancer RRBS data and highlighted that DNAm alterations in cancer driver genes from unambiguous CpGs uniquely called by T2T-CHM13 may improve our understanding of cancer biology and hold possible significant clinical translational value. This evidence concerns the gene CBS and breast carcinoma.